{"id":14817,"date":"2024-09-27T08:43:18","date_gmt":"2024-09-27T08:43:18","guid":{"rendered":"https:\/\/www.drknowhk.org\/?p=14817"},"modified":"2024-10-16T08:52:16","modified_gmt":"2024-10-16T08:52:16","slug":"covid-preventive-drug-should-work-against-circulating-variants-fda-now-says","status":"publish","type":"post","link":"https:\/\/www.drknowhk.org\/mo\/covid-preventive-drug-should-work-against-circulating-variants-fda-now-says\/","title":{"rendered":"COVID Preventive Drug Should Work Against Circulating Variants, FDA Now Says"},"content":{"rendered":"<p class=\"qtranxs-available-languages-message qtranxs-available-languages-message-mo\">\u5c0d\u4e0d\u8d77\uff0c\u6b64\u5185\u5bb9\u53ea\u9069\u7528\u65bc<a href=\"https:\/\/www.drknowhk.org\/en\/wp-json\/wp\/v2\/posts\/14817\" class=\"qtranxs-available-language-link qtranxs-available-language-link-en\" title=\"English\">English<\/a>\u3002<\/p><p>By Katherine Kahn<\/p>\n<p>Source Medpagetoday<\/p>\n<p>The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently circulating SARS-CoV-2 variants, including KP.3.1.1 and LB.1.<\/p>\n<p>&#8220;Based on current CDC Nowcast estimates and variant spike receptor binding domain similarity to tested variants, FDA anticipates Pemgarda will retain activity against the currently circulating variants in the U.S.,&#8221; the agency said in a press releaseopens in a new tab or window.<\/p>\n<p>This is welcome news for patients at risk for severe COVID-19, such as those with immunocompromising conditions. Pemivibart remains the only available monoclonal antibodyopens in a new tab or window for the prevention of COVID-19 in this population.<\/p>\n<p>In late August, the FDA had revised the emergency use authorization (EUA) for pemivibart, adding a limitation of authorized useopens in a new tab or window over concerns that KP.3.1.1 may have had substantially reduced susceptibility to the drug. The FDA indicated that pemivibart should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%.<\/p>\n<p>Read more <a href=\"https:\/\/www.medpagetoday.com\/infectiousdisease\/covid19\/112152\">https:\/\/www.medpagetoday.com\/infectiousdisease\/covid19\/112152<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>\u5c0d\u4e0d\u8d77\uff0c\u6b64\u5185\u5bb9\u53ea\u9069\u7528\u65bcEnglish\u3002By Katherine Kahn Source Medpagetoday The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently circulating SARS-CoV-2 variants, including KP.3.1.1 and LB.1. &#8220;Based on current CDC Nowcast estimates and variant spike receptor binding domain similarity to tested variants, FDA anticipates Pemgarda will retain activity against the currently circulating [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":14818,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[21,91,52],"tags":[],"class_list":["post-14817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-scientific-reports","category-vaccination","category-virology-pathophysiology"],"_links":{"self":[{"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/posts\/14817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/comments?post=14817"}],"version-history":[{"count":1,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/posts\/14817\/revisions"}],"predecessor-version":[{"id":14819,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/posts\/14817\/revisions\/14819"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/media\/14818"}],"wp:attachment":[{"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/media?parent=14817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/categories?post=14817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drknowhk.org\/mo\/wp-json\/wp\/v2\/tags?post=14817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}